Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Soledad Retamozo, Antoni Sisó-Almirall, Alejandra Flores-Chávez, Manuel Ramos-Casals & Pilar Brito-Zerón. (2021) An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opinion on Pharmacotherapy 22:17, pages 2359-2371.
Read now
Read now
Lauren M. Mathias & William Stohl. (2020) Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opinion on Therapeutic Targets 24:12, pages 1283-1302.
Read now
Read now
Ahmed M. Abu El-Asrar, Nele Berghmans, Saleh A. Al-Obeidan, Priscilla W. Gikandi, Ghislain Opdenakker, Jo Van Damme & Sofie Struyf. (2020) Local Cytokine Expression Profiling in Patients with Specific Autoimmune Uveitic Entities. Ocular Immunology and Inflammation 28:3, pages 453-462.
Read now
Read now
Robert J. Benschop, Chi-Kin Chow, Yu Tian, James Nelson, Barbra Barmettler, Shane Atwell, David Clawson, Qing Chai, Bryan Jones, Jon Fitchett, Stacy Torgerson, Yan Ji, Holly Bina, Ningjie Hu, Mahmoud Ghanem, Joseph Manetta, Victor J. Wroblewski, Jirong Lu & Barrett W. Allan. (2019) Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. mAbs 11:6, pages 1175-1190.
Read now
Read now
Aleksander Lenert, Timothy B Niewold & Petar Lenert. (2017) Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Design, Development and Therapy 11, pages 747-757.
Read now
Read now
Shawn Shetty & A. Razzaque Ahmed. (2017) Rituximab in the treatment of pemphigus. Expert Opinion on Orphan Drugs 5:1, pages 99-109.
Read now
Read now
Jorge Medina-Rosas, Hanan Al-Rayes, Ahmed T. Moustafa & Zahi Touma. (2016) Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. Expert Opinion on Biological Therapy 16:10, pages 1225-1238.
Read now
Read now
Huza Zhang, William Chambers, Savino Sciascia & Maria J. Cuadrado. (2016) Emerging therapies in systemic lupus erythematous: from clinical trial to the real life. Expert Review of Clinical Pharmacology 9:5, pages 681-694.
Read now
Read now
Estafania Cogollo, Marta Amaral Silva & David Isenberg. (2015) Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Design, Development and Therapy 9, pages 1331-1339.
Read now
Read now
Articles from other publishers (44)
Lubna Abuqayyas, Po‐Wei Chen, Marcia Teixeira dos Santos, Jane R. Parnes, Sameer Doshi, Sandeep Dutta & Brett E. Houk. (2023)
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of
BAFF
and
ICOSL
: Analyses of Phase I Clinical Trials
. Clinical Pharmacology & Therapeutics 114:2, pages 371-380.
Crossref
Crossref
Zhilang Lin, Nannan Yu, Cheng Cheng, Bei Jin, Qiufang Zhang, Hongjie Zhuang & Xiaoyun Jiang. (2023) Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement. Lupus 32:5, pages 680-687.
Crossref
Crossref
Melek Kechida. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
15
.
Yaqi Wang, Shengxiang Xiao, Yumin Xia & Huixia Wang. (2021) The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clinical Reviews in Allergy & Immunology 63:2, pages 152-165.
Crossref
Crossref
Riccardo Masetti, Alessandra Tiri, Anna Tignanelli, Elena Turrini, Alberto Argentiero, Andrea Pession & Susanna Esposito. (2021) Autoimmunity and cancer. Autoimmunity Reviews 20:9, pages 102882.
Crossref
Crossref
Eirini Sevdali, Violeta Block Saldana, Matthaios Speletas & Hermann Eibel. (2021) BAFF receptor polymorphisms and deficiency in humans. Current Opinion in Immunology 71, pages 103-110.
Crossref
Crossref
Ram P. Singh, Bevra H. Hahn & David S. Bischoff. (2021) Effects of Peptide-Induced Immune Tolerance on Murine Lupus. Frontiers in Immunology 12.
Crossref
Crossref
Lei Zhu, Binyao Chen & Wenru Su. (2021) A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis. Frontiers in Immunology 12.
Crossref
Crossref
Ji Won Min, Yoo-Jin Shin, Hyeyoung Lee, Bo-Mi Kim, Ki Hyun Park, Kyoung Chan Doh, Tae-Min Kim, Sun Woo Lim, Chul Woo Yang, Eun-Jee Oh & Byung Ha Chung. (2021) BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model. International Journal of Molecular Sciences 22:2, pages 861.
Crossref
Crossref
Stephan Klöß, Susann Dehmel, Armin Braun, Michael J. Parnham, Ulrike Köhl & Susanne Schiffmann. (2020) From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Claire Leibler, Allan Thiolat, Rebecca A. Elsner, Khalil El Karoui, Chloe Samson & Philippe Grimbert. (2019) Costimulatory blockade molecules and B-cell–mediated immune response: current knowledge and perspectives. Kidney International 95:4, pages 774-786.
Crossref
Crossref
Christine Kowalczyk-Quintas, Dehlia Chevalley, Laure Willen, Camilla Jandus, Michele Vigolo & Pascal Schneider. (2018) Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab. Frontiers in Immunology 9.
Crossref
Crossref
Michele Vigolo, Melissa G. Chambers, Laure Willen, Dehlia Chevalley, Klaus Maskos, Alfred Lammens, Aubry Tardivel, Dolon Das, Christine Kowalczyk-Quintas, Sonia Schuepbach-Mallepell, Cristian R. Smulski, Mahya Eslami, Antonius Rolink, Edith Hummler, Eileen Samy, Yves Fomekong Nanfack, Fabienne Mackay, Maofu Liao, Henry Hess, Xuliang Jiang & Pascal Schneider. (2018) A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors. Nature Communications 9:1.
Crossref
Crossref
Eva Schrezenmeier, David Jayne & Thomas Dörner. (2018) Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. Journal of the American Society of Nephrology 29:3, pages 741-758.
Crossref
Crossref
Shu-Han Yang, Cai-yue Gao, Liang Li, Christopher ChangPatrick S.C. LeungM. Eric GershwinZhe-Xiong Lian. (2018) The molecular basis of immune regulation in autoimmunity. Clinical Science 132:1, pages 43-67.
Crossref
Crossref
Feng Zhang, Jin-Ling Shu, Ying Li, Yu-Jing Wu, Xian-Zheng Zhang, Le Han, Xiao-Yu Tang, Chen Wang, Qing-Tong Wang, Jing-Yu Chen, Yan Chang, Hua-Xun Wu, Ling-Ling Zhang & Wei Wei. (2017) CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents. Frontiers in Pharmacology 8.
Crossref
Crossref
Masaru Ishii. (2017) Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23. British Journal of Pharmacology 174:13, pages 1875-1880.
Crossref
Crossref
Michael Croft & Richard M. Siegel. (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nature Reviews Rheumatology 13:4, pages 217-233.
Crossref
Crossref
Ngoc Lan Tran, Pascal Schneider & Marie-Laure Santiago-Raber. (2017) TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus. European Journal of Immunology 47:4, pages 713-723.
Crossref
Crossref
Weihua Hou, Xianchao Meng, Yuxiong Wang, Wei Mo, Yi Wu & Min Yu. (2017)
Characterization and high-yield production of non-
N
-glycosylated recombinant human BCMA-Fc in
Pichia pastoris
. Engineering in Life Sciences 17:2, pages 96-106.
Crossref
Crossref
Mathieu Uzzan, Jean-Frederic Colombel, Andrea Cerutti, Xavier Treton & Saurabh Mehandru. (2016) B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Digestive Diseases and Sciences 61:12, pages 3407-3424.
Crossref
Crossref
Thomas Dörner & Peter E. Lipsky. (2016) Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE. Nature Reviews Rheumatology 12:11, pages 645-657.
Crossref
Crossref
Pilar Brito-Zerón, Soledad Retamozo, Hoda Gheitasi & Manuel Ramos-Casals. (2016) Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. Drugs 76:17, pages 1601-1623.
Crossref
Crossref
Ji Won Min, Kyoung Woon Kim, Bo-Mi Kim, Kyoung Chan Doh, Min Seok Choi, Bum Soon Choi, Cheol Whee Park, Chul Woo Yang, Yong-Soo Kim, Eun-Jee Oh & Byung Ha Chung. (2016) Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients. PLOS ONE 11:9, pages e0162964.
Crossref
Crossref
Christine Kowalczyk-Quintas, Sonia Schuepbach-Mallepell, Michele Vigolo, Laure Willen, Aubry Tardivel, Cristian R. Smulski, Timothy S. Zheng, Jennifer Gommerman, Henry Hess, Jacques-Eric Gottenberg, Fabienne Mackay, Olivier Donzé & Pascal Schneider. (2016) Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B Cell Hyperplasia. Journal of Biological Chemistry 291:38, pages 19826-19834.
Crossref
Crossref
Jennifer Witcher, Roy Fleischmann, Vishala L. Chindalore, Ryan J. Hansen, Leijun Hu, David Radtke, James Voelker, Elisa Gomez & Juliet McColm. (2016) Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. British Journal of Clinical Pharmacology 81:5, pages 908-917.
Crossref
Crossref
Lindsay K. Ward-Kavanagh, Wai Wai Lin, John R. Šedý & Carl F. Ware. (2016) The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity 44:5, pages 1005-1019.
Crossref
Crossref
Baolan Sun, Lin Li, Meiyu Xu, Xudong Wang, Feng Wang & Hongbing Ni. (2016) Significance of BAFF/APRIL Expression and Their Receptors in Pediatric Patients With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 38:3, pages 167-172.
Crossref
Crossref
Giordano Egiziano, Ann E. Clarke, Rosalind Ramsey-Goldman & Sasha Bernatsky. (2016) Malignancy in Systemic Lupus Erythematosus. Current Treatment Options in Rheumatology 2:1, pages 13-20.
Crossref
Crossref
D A Isenberg, M Petri, K Kalunian, Y Tanaka, M B Urowitz, R W Hoffman, M Morgan-Cox, N Iikuni, M Silk & D J Wallace. (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases 75:2, pages 323-331.
Crossref
Crossref
Giordano Egiziano, Sasha Bernatsky & Ami A. Shah. (2016) Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. Best Practice & Research Clinical Rheumatology 30:1, pages 53-62.
Crossref
Crossref
Roberta Fenoglio, Fernando Fervenza & Dario Roccatello. 2016. Connective Tissue Disease. Connective Tissue Disease
239
261
.
Sander W. Tas & Dominique L. P. Baeten. 2016. Suppression and Regulation of Immune Responses. Suppression and Regulation of Immune Responses
143
155
.
Cheol Lee, Jeong-Whan Park, Ja Hee Suh & Kyung Chul Moon. (2015) High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma. Pathology - Research and Practice 211:11, pages 824-828.
Crossref
Crossref
Zi-Zhen Xu, Bing-Bing Zhao, Hong Xiong, Bei-Wen Wei & Ye-Fei Wang. (2015) Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance. International Journal of Hematology 102:4, pages 394-400.
Crossref
Crossref
Lara Valor & Francisco Javier López-Longo. (2015) Modulación del sistema de supervivencia y maduración del linfocito B: presente y futuro de una nueva estrategia terapéutica en el lupus eritematoso sistémico. Medicina Clínica 145:5, pages 206-210.
Crossref
Crossref
Lara Valor & Francisco Javier López-Longo. (2015) Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus. Medicina Clínica (English Edition) 145:5, pages 206-210.
Crossref
Crossref
Sandra A. Morais, Andreia Vilas-Boas & David A. Isenberg. (2015) B-cell survival factors in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease 7:4, pages 122-151.
Crossref
Crossref
Ignasi Rodriguez-Pintó, Gerard Espinosa & Ricard Cervera. (2015) Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. Clinical Investigation 5:6, pages 561-571.
Crossref
Crossref
Sonia Schuepbach-Mallepell, Dolon Das, Laure Willen, Michele Vigolo, Aubry Tardivel, Luc Lebon, Christine Kowalczyk-Quintas, Josquin Nys, Cristian Smulski, Timothy S. Zheng, Klaus Maskos, Alfred Lammens, Xuliang Jiang, Henry Hess, Seng-Lai Tan & Pascal Schneider. (2015) Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties. Journal of Biological Chemistry 290:26, pages 16330-16342.
Crossref
Crossref
J. Kwun, E. Page, J.J. Hong, A. Gibby, J. Yoon, A.B. Farris, F. Villinger & S. Knechtle. (2015) Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model. American Journal of Transplantation 15:3, pages 815-822.
Crossref
Crossref
Yi Zhang, Jun Li, Ya-Min Zhang, Xiao-Ming Zhang & Juan Tao. (2015) Effect of TACI Signaling on Humoral Immunity and Autoimmune Diseases. Journal of Immunology Research 2015, pages 1-12.
Crossref
Crossref
Evelyn Tsantikos, Timothy A Gottschalk, Mhairi J Maxwell & Margaret L Hibbs. (2014) Role of the Lyn tyrosine kinase in the development of autoimmune disease. International Journal of Clinical Rheumatology 9:5, pages 519-535.
Crossref
Crossref
Noa Schwartz, Beatrice Goilav & Chaim Putterman. (2014) The pathogenesis, diagnosis and treatment of lupus nephritis. Current Opinion in Rheumatology 26:5, pages 502-509.
Crossref
Crossref